Interestingly, high expression of YTHDF2 was associated with poor survival in glioma patients with WT p53 but not mutant p53 (Fig. 2g), suggesting that high YTHDF2 expression is correlated to poor prognosis in p53 WT glioma patients and the elevated level of YTHDF2 by mutant p53 is a sufficient dominant influencer of patient survival among p53 mutant glioma patients. This evidence concerns the gene YTHDF2 and central nervous system cancer.